Wednesday, July 8, 2026

Drug profile · INN

calcium chloride

calcium chloride (DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER) is a dihydrofolate reductase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: irrigation. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 91
News articles 0
Drug details — calcium chloride
US status
approved
Class
Route
IRRIGATION
Patents
20
Programs
91
Data quality
0.89

Quick answer

calcium chloride (DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER) is a dihydrofolate reductase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: irrigation. Current US regulatory status: approved.

Key facts

INN calcium chloride
Brand DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Mechanism Dihydrofolate reductase inhibitor
Route IRRIGATION
Formulation INJECTABLE

Mechanism of action

Dihydrofolate reductase inhibitor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 0.2 mg/kg ketamine Phase 3 · United Therapeutics Europe · Depression
  2. 2.0 mg intravitreal aflibercept Phase 3 · Regeneron UK · Diabetic Macular Edema
  3. 20200041 Phase 3 · Amgen · Extensive stage small cell lung cancer (ES-SCLC)
  4. 25% AgNO3 solution followed by 5% NaF Phase 3 · University of Hong · Early Childhood Caries
  5. APHP200073 Phase 3 · PARItec · Erythema multiforme (EM) in its severe form managed at the h
  6. APHP230864 Phase 3 · PARItec · Cytoreductive surgery with hyperthermic intraperitoneal chem
  7. GTX-102-CL302 Phase 3 · Anaxis Pharma · Angelman Syndrome
  8. ION 682884, ION 682884 Phase 3 · IONIS PHARMACEUTICALS · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
  1. US 12077549

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. CA 3244873

    TRAITEMENT PRÉVENTIF DE LA MIGRAINE

    Expires Wed Sep 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11692030

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. WO 2023077094

    TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR

    Expires Wed Apr 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 2023130736

    METHODS OF TREATING MIGRAINE

    Expires Wed Apr 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11622968

    Heterocyclic modulators of lipid synthesis

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11612608

    Methods of treating oral mucositis

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11598782

    Biomarkers and methods for detection of seizures and epilepsy

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 2022380379

    PHARMACEUTICAL COMPOUNDS

    Expires Wed Nov 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 2021387969

    BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS

    Expires Wed Dec 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. CA 3177686

    COMPOSITIONS COMPRENANT DE LA TROPOELASTINE RETICULEE A DE L'ACIDE HYALURONIQUE ET LEURS PROCEDES D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11066433

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11008622

    Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. CA 3152006

    TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE

    Expires Wed Feb 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10610533

    Methods of treating oral mucositis

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10597415

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. WO 2020012244

    TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB

    Expires Wed Jan 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10350193

    Super-oxide dismutase mimetics

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. WO 2019016609

    TRAITEMENT DE LÉSIONS NON INFLAMMATOIRES

    Expires Wed Jan 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is calcium chloride?

calcium chloride (DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER) is a dihydrofolate reductase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: irrigation. Current US regulatory status: approved.

What is the brand name for calcium chloride?

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER is a marketed brand name for calcium chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of calcium chloride?

calcium chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.